Effect of repeated dosing on rifampin exposure in BALB/c mice

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 1, 2013, Pages 33-38

  Hosagrahara, Vinayak ^a   Reddy, Jitendar ^a   Ganguly, Samit ^a   Panduga, Vijender ^a   Ahuja, Vijaykamal ^a   Parab, Manish ^a   Giridhar, Jayashree ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CYP3A; Induction; Mouse; Pgp; Rifampin

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DIGOXIN; MULTIDRUG RESISTANCE PROTEIN; RIFAMPICIN; VERAPAMIL; CYTOCHROME P450;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG HALF LIFE; DRUG METABOLISM; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; P-GLYCOPROTEIN; RIFAMPIN; TIME FACTORS;

EID: 84874932404     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.01.017     Document Type: Article

References (27)

1. V. Balasubramanian, S. Solapure, S. Gaonkar, K.N. Mahesh Kumar, R.K. Shandil, A. Deshpande, N. Kumar, K.G. Vishwas, V. Panduga, J. Reddy, S. Ganguly, A. Louie, and G.L. Drusano Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model Antimicrob. Agents Chemother. 56 2012 3054 3057
2. T.S. Balganesh, P.M. Alzari, and S.T. Cole Rising standards for tuberculosis drug development Trends Pharmacol. Sci. 29 2008 576 581
3. S.T. Cole, and G. Riccardi New tuberculosis drugs on the horizon Curr. Opin. Microbiol. 14 2011 570 576
4. A.S. Dharmadhikari, and E.A. Nardell What animal models teach humans about tuberculosis Am J. Respir. Cell. Mol. Biol. 39 2008 503 508
5. B. Greiner, M. Eichelbaum, P. Fritz, H.P. Kreichgauer, O. von Richter, J. Zundler, and H.K. Kroemer The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin J. Clin. Invest. 104 1999 147 153
6. U.D. Gupta, and V.M. Katoch Animal models of tuberculosis Tuberculosis (Edinb.) 85 2005 277 293 (Pubitemid 41617383)
7. R. Jayaram, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R.K. Shandil, E. Kantharaj, and V. Balasubramanian Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis Antimicrob. Agents Chemother. 47 2003 2118 2124 (Pubitemid 36753560)
8. R. Jayaram, R.K. Shandil, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis Antimicrob. Agents Chemother. 48 2004 2951 2957 (Pubitemid 38989160)
9. O. Jonsson, R.P. Villar, L.B. Nilsson, C. Norsten-Hoog, J. Brogren, M. Eriksson, K. Konigsson, and A. Samuelsson Capillary microsampling of 25 microl blood for the determination of toxicokinetic parameters in regulatory studies in animals Bioanalysis 4 2012 661 674
10. T. Kaneko, C. Cooper, and K. Mdluli Challenges and opportunities in developing novel drugs for TB Future Med. Chem. 3 2011 1373 1400
11. E.L. LeCluyse Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics Chem. Biol. Interact 134 2001 283 289
12. X.G. Liu, P.K. Narang, and R.C. Li Induction of hepatic and presystemic metabolism of antipyrine in the mice. rifampicin versus rifabutin Eur. J. Drug Metab. Pharmacokinet. 26 2001 209 213 (Pubitemid 34076165)
13. U. Loos, E. Musch, J.C. Jensen, G. Mikus, H.K. Schwabe, and M. Eichelbaum Pharmacokinetics of oral and intravenous rifampicin during chronic administration Klin. Wochenschr. 63 1985 1205 1211 (Pubitemid 16169743)
14. X. Ma, Y. Shah, C. Cheung, G.L. Guo, L. Feigenbaum, K.W. Krausz, J.R. Idle, and F.J. Gonzalez The Pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A Drug Metab. Dispos. 35 2007 194 200 (Pubitemid 46148730)
15. V. Makarov, G. Manina, K. Mikusova, U. Mollmann, O. Ryabova, B. Saint-Joanis, N. Dhar, M.R. Pasca, S. Buroni, A.P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J.D. McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R.K. Shandil, V. Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, and S.T. Cole Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis Science 324 2009 801 804
16. C.J. Matheny, R.Y. Ali, X. Yang, and G.M. Pollack Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues Drug Metab. Dispos. 32 2004 1008 1014 (Pubitemid 39096062)
17. E. Nuermberger, S. Tyagi, R. Tasneen, K.N. Williams, D. Almeida, I. Rosenthal, and J.H. Grosset Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis Antimicrob. Agents Chemother. 52 2008 1522 1524 (Pubitemid 351522025)
18. T. Omura, and R. Sato The carbon monoxide-binding pigment of liver microsomes. Ii. solubilization, purification, and properties J. Biol. Chem. 239 1964 2379 2385
19. D. Pessayre, and P. Mazel Induction and inhibition of hepatic drug metabolizing enzymes by rifampin Biochem. Pharmacol. 25 1976 943 949
20. M.L. Reitman, X. Chu, X. Cai, J. Yabut, R. Venkatasubramanian, S. Zajic, J.A. Stone, Y. Ding, R. Witter, C. Gibson, K. Roupe, R. Evers, J.A. Wagner, and A. Stoch Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design Clin. Pharmacol. Ther. 89 2011 234 242
21. I.M. Rosenthal, K. Williams, S. Tyagi, C.A. Peloquin, A.A. Vernon, W.R. Bishai, J.H. Grosset, and E.L. Nuermberger Potent twice-weekly rifapentine-containing regimens in murine tuberculosis Am. J. Respir. Crit. Care Med. 174 2006 94 101 (Pubitemid 43955249)
22. I.M. Rosenthal, M. Zhang, K.N. Williams, C.A. Peloquin, S. Tyagi, A.A. Vernon, W.R. Bishai, R.E. Chaisson, J.H. Grosset, and E.L. Nuermberger Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model PLoS Med. 4 2007 e344
23. E.G. Schuetz, A.H. Schinkel, M.V. Relling, and J.D. Schuetz P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans Proc. Natl. Acad. Sci. USA 93 1996 4001 4005 (Pubitemid 26144235)
24. R.K. Shandil, R. Jayaram, P. Kaur, S. Gaonkar, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy Antimicrob. Agents Chemother. 51 2007 576 582 (Pubitemid 46185275)
25. J. van den Boogaard, G.S. Kibiki, E.R. Kisanga, M.J. Boeree, and R.E. Aarnoutse New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development Antimicrob. Agents Chemother. 53 2009 849 862
26. C. Wandel, R.B. Kim, S. Kajiji, P. Guengerich, G.R. Wilkinson, and A.J. Wood P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies Cancer Res. 59 1999 3944 3948 (Pubitemid 29393559)
27. M. Zhang, S.Y. Li, I.M. Rosenthal, D.V. Almeida, Z. Ahmad, P.J. Converse, C.A. Peloquin, E.L. Nuermberger, and J.H. Grosset Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice Am. J. Respir. Crit. Care Med. 183 2011 1254 1261